Skip to content

Study · In vitro (cells) · 2007

6 results

Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC

Endocrine-related cancer1 Mar 2007Cited by 96 (Europe PMC)

PMID17395978 (opens in a new tab)DOI10.1677/erc-06-0026 (opens in a new tab)PepBankPUB-17395978
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In responder human adenoma cultures, pasireotide reduced VEGF secretion.

    In plain wordsIn cells from responder human adenomas, pasireotide reduced VEGF secretion.

    Peptide
    Pasireotide
    Outcome
    DecreaseVEGF secretion in responders
    Study

    humann: not reported in source

    Non-functioning pituitary adenoma primary cultures
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    VEGF secretion and cell viability were reduced by SRIF and pasireotide in the 'responder' group, but not in the 'non-responder' group, including NFA expressing SSTR5.
    2 context sentences
    Summary · context
    The aim of our study was to clarify the possible effects of a multireceptor SRIF ligand on VEGF secretion and cell proliferation in human NFA primary cultures.
    Summary · context
    Primary cultures were tested with SRIF and with pasireotide.
  2. 02LabIn vitro (cells)Efficacy outcome

    In responder human adenoma cultures, pasireotide reduced cell viability.

    In plain wordsIn cells from responder human adenomas, pasireotide reduced cell viability.

    Peptide
    Pasireotide
    Outcome
    DecreaseCell viability in responders
    Study

    humann: not reported in source

    Non-functioning pituitary adenoma primary cultures
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    VEGF secretion and cell viability were reduced by SRIF and pasireotide in the 'responder' group, but not in the 'non-responder' group, including NFA expressing SSTR5.
    2 context sentences
    Summary · context
    The aim of our study was to clarify the possible effects of a multireceptor SRIF ligand on VEGF secretion and cell proliferation in human NFA primary cultures.
    Summary · context
    Primary cultures were tested with SRIF and with pasireotide.
  3. 03LabIn vitro (cells)Efficacy outcome

    In non-responder human adenoma cultures, pasireotide did not reduce VEGF secretion.

    In plain wordsIn cells from non-responder human adenomas, pasireotide did not reduce VEGF secretion.

    Peptide
    Pasireotide
    Outcome
    No significant changeVEGF secretion in non-responders
    Study

    humann: not reported in source

    Non-functioning pituitary adenoma primary cultures
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    VEGF secretion and cell viability were reduced by SRIF and pasireotide in the 'responder' group, but not in the 'non-responder' group, including NFA expressing SSTR5.
    2 context sentences
    Summary · context
    The aim of our study was to clarify the possible effects of a multireceptor SRIF ligand on VEGF secretion and cell proliferation in human NFA primary cultures.
    Summary · context
    Primary cultures were tested with SRIF and with pasireotide.
  4. 04LabIn vitro (cells)Efficacy outcome

    In non-responder human adenoma cultures, pasireotide did not reduce cell viability.

    In plain wordsIn cells from non-responder human adenomas, pasireotide did not reduce cell viability.

    Peptide
    Pasireotide
    Outcome
    No significant changeCell viability in non-responders
    Study

    humann: not reported in source

    Non-functioning pituitary adenoma primary cultures
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    VEGF secretion and cell viability were reduced by SRIF and pasireotide in the 'responder' group, but not in the 'non-responder' group, including NFA expressing SSTR5.
    2 context sentences
    Summary · context
    The aim of our study was to clarify the possible effects of a multireceptor SRIF ligand on VEGF secretion and cell proliferation in human NFA primary cultures.
    Summary · context
    Primary cultures were tested with SRIF and with pasireotide.
  5. 05LabIn vitro (cells)Efficacy outcome

    In human adenoma cultures, pasireotide completely blocked forskolin-induced VEGF secretion.

    In plain wordsIn cells from human adenomas, pasireotide completely blocked forskolin-induced VEGF secretion.

    Peptide
    Pasireotide
    Outcome
    DecreaseForskolin-induced VEGF secretion
    Study

    humann: not reported in source

    Non-functioning pituitary adenoma primary cultures
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SRIF and pasireotide completely blocked forskolin-induced VEGF secretion.
    2 context sentences
    Summary · context
    The aim of our study was to clarify the possible effects of a multireceptor SRIF ligand on VEGF secretion and cell proliferation in human NFA primary cultures.
    Summary · context
    Primary cultures were tested with SRIF and with pasireotide.
  6. 06LabIn vitro (cells)Efficacy outcome

    In human adenoma cultures, pasireotide completely blocked the promoting effects of VEGF on cell viability.

    In plain wordsIn cells from human adenomas, pasireotide blocked the increase in cell viability from VEGF.

    Peptide
    Pasireotide
    Outcome
    DecreaseVEGF-promoted cell viability
    Study

    humann: not reported in source

    Non-functioning pituitary adenoma primary cultures
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, SRIF and pasireotide completely abrogated the promoting effects of VEGF on NFA cell viability.
    2 context sentences
    Summary · context
    The aim of our study was to clarify the possible effects of a multireceptor SRIF ligand on VEGF secretion and cell proliferation in human NFA primary cultures.
    Summary · context
    Primary cultures were tested with SRIF and with pasireotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.